{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.6","upperLimit":"9.8","value":"5.21"},{"groupId":"OG001","lowerLimit":"1.3","upperLimit":"8.8","value":"4.46"}]}],"title":"Baseline Estradiol"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.5","upperLimit":"21.6","value":"7.55"},{"groupId":"OG001","lowerLimit":"3.3","upperLimit":"23.7","value":"9.26"}]}],"title":"Week 24 Estradiol"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"description":"To describe patterns of estradiol over the twenty-four week study period.","dispersionType":"Full Range","groups":[{"description":"This is a prospective longitudinal pilot study, and the targeted patient population is postmenopausal women with breast cancer being treated with adjuvant aromatase inhibitors who are initiated on vaginal 17β-estradiol to relieve symptoms of atrophic vaginitis.","id":"OG000","title":"Letrozole"},{"description":"This is a prospective longitudinal pilot study, and the targeted patient population is postmenopausal women with breast cancer being treated with adjuvant aromatase inhibitors who are initiated on vaginal 17β-estradiol to relieve symptoms of atrophic vaginitis.","id":"OG001","title":"Anastrozole"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"24 weeks","title":"Change in Serum Estradiol Baseline to Week 24","type":"SECONDARY","unitOfMeasure":"pg/ mL"}